The regulatory mechanisms and translational applications of non-coding RNA in SARS-CoV-2 infection-related cardiovascular pathology
By
Ziwei Cao
Yurong Song
Jing Li
Yuan Cao
July 15, 2026
Clinical Scorecard: Regulatory Roles and Clinical Implications of Non-Coding RNAs in Cardiovascular Issues Associated with SARS-CoV-2 Infection
At a Glance
Category Detail
Condition COVID-19-related cardiovascular complications Key Mechanisms Involvement of non-coding RNAs in gene expression regulation, apoptosis, metabolic reprogramming, and cell communication. Target Population Patients with SARS-CoV-2 infection, particularly those with cardiovascular comorbidities. Care Setting Clinical settings managing COVID-19 patients with cardiovascular complications.
Key Highlights
Over 20%-25% of hospitalized COVID-19 patients exhibit myocardial injury. Cardiovascular complications include acute coronary syndromes, myocarditis, and arrhythmias. Non-coding RNAs play critical roles in regulating inflammation and thrombosis. Dysregulated immune response and cytokine storm contribute to cardiovascular damage. ncRNAs have potential as biomarkers and therapeutic targets in COVID-19-related cardiovascular disease. Guideline-Based Recommendations
Diagnosis
Monitor cardiac troponin levels in hospitalized COVID-19 patients. Management
Consider the role of ncRNAs in therapeutic strategies for cardiovascular complications. Monitoring & Follow-up
Regular assessment of cardiovascular function in COVID-19 patients. Risks
Increased risk of severe cardiovascular complications in patients with preexisting conditions. Patient & Prescribing Data
Patients with COVID-19 and cardiovascular comorbidities.
Emerging ncRNA-based therapies may offer new treatment avenues.
Clinical Best Practices
Integrate multi-omics data to understand ncRNA roles in cardiovascular pathology. Evaluate the potential of ncRNAs as diagnostic and prognostic biomarkers. Related Resources & Content
